IRIS UniCatt

Armuzzi, Alessandro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.040
NA - Nord America 7.066
AS - Asia 5.723
SA - Sud America 1.279
AF - Africa 144
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 18
AN - Antartide 1
Totale 22.295
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.857
DE - Germania 3.656
SG - Singapore 2.821
CN - Cina 1.524
SE - Svezia 1.167
BR - Brasile 1.071
IT - Italia 797
UA - Ucraina 525
FR - Francia 412
GB - Regno Unito 339
IE - Irlanda 338
VN - Vietnam 249
IN - India 237
FI - Finlandia 226
ID - Indonesia 220
RU - Federazione Russa 166
TR - Turchia 156
PL - Polonia 109
AR - Argentina 98
CA - Canada 93
HK - Hong Kong 77
MX - Messico 71
BD - Bangladesh 70
JP - Giappone 58
KR - Corea 49
IQ - Iraq 46
ES - Italia 45
AT - Austria 42
BE - Belgio 40
NL - Olanda 39
ZA - Sudafrica 32
IR - Iran 30
EC - Ecuador 29
CZ - Repubblica Ceca 24
SA - Arabia Saudita 24
PK - Pakistan 23
AU - Australia 22
CI - Costa d'Avorio 21
CO - Colombia 19
CH - Svizzera 18
MA - Marocco 18
UZ - Uzbekistan 18
VE - Venezuela 18
EG - Egitto 16
EU - Europa 15
LT - Lituania 15
TN - Tunisia 15
IL - Israele 14
PT - Portogallo 14
JO - Giordania 13
AZ - Azerbaigian 12
JM - Giamaica 12
KE - Kenya 12
UY - Uruguay 12
AE - Emirati Arabi Uniti 11
HU - Ungheria 10
DZ - Algeria 9
PE - Perù 9
CL - Cile 8
OM - Oman 8
PH - Filippine 8
AL - Albania 7
BG - Bulgaria 7
CR - Costa Rica 7
KZ - Kazakistan 7
NP - Nepal 7
PY - Paraguay 7
RO - Romania 7
RS - Serbia 6
TT - Trinidad e Tobago 6
BO - Bolivia 5
ET - Etiopia 5
HN - Honduras 5
LV - Lettonia 5
BY - Bielorussia 4
BZ - Belize 4
GR - Grecia 4
LB - Libano 4
MO - Macao, regione amministrativa speciale della Cina 4
AO - Angola 3
BN - Brunei Darussalam 3
CG - Congo 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
EE - Estonia 3
KG - Kirghizistan 3
PA - Panama 3
PS - Palestinian Territory 3
TH - Thailandia 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BH - Bahrain 2
GT - Guatemala 2
KH - Cambogia 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
MD - Moldavia 2
MY - Malesia 2
NG - Nigeria 2
Totale 22.261
Salva come PNG Salva come JPEG
Città #
Singapore 1.406
Chandler 1.277
Cologne 1.211
Ashburn 688
Beijing 360
Dublin 328
Jacksonville 324
San Mateo 264
New York 229
Los Angeles 209
Jakarta 202
Hefei 181
Nanjing 171
Milan 160
Munich 158
Ann Arbor 150
Wilmington 144
Boston 136
Dearborn 134
Cattolica 123
Nürnberg 119
Chicago 118
Princeton 107
Izmir 102
Rome 100
São Paulo 90
Ho Chi Minh City 86
Marseille 83
Houston 79
Moscow 75
Frankfurt am Main 72
Hong Kong 72
Seattle 67
Helsinki 63
Bremen 62
Dallas 61
Essen 61
Nanchang 60
Woodbridge 59
Lawrence 57
Hanoi 55
Redwood City 53
The Dalles 51
Warsaw 51
Buffalo 47
Seoul 47
Lancaster 46
Fairfield 44
Hangzhou 44
Pune 43
Kent 42
Tokyo 42
Boardman 39
Norwalk 38
Turku 37
Brussels 36
Rio de Janeiro 36
Kraków 35
Mountain View 35
Hebei 34
Belo Horizonte 31
Brooklyn 31
Shenyang 31
Nuremberg 30
Hyderabad 29
Shanghai 28
Stockholm 28
Santa Clara 27
Tianjin 27
Toronto 27
Augusta 26
Jiaxing 26
Lappeenranta 26
London 26
University Park 26
Denver 24
Detroit 24
Guangzhou 24
Kunming 24
Baghdad 23
Changsha 23
Chennai 23
Düsseldorf 23
Leawood 23
Mexico City 23
Montreal 23
Abidjan 21
Atlanta 20
Brasília 20
Johannesburg 19
San Francisco 19
Zhengzhou 19
Campinas 18
Phoenix 18
San Jose 18
Vienna 18
Tomsk 17
Amsterdam 16
Fremont 16
Jinan 16
Totale 11.234
Salva come PNG Salva come JPEG
Nome #
3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: Diagnosis and medical management 1.340
A) Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease. 350
A) Infliximab in the treatment of steroid-dependent ulcerative colitis. 300
Asthma in patients admitted to emergency department for COVID-19: prevalence and risk of hospitalization 249
13C-methionine breath tests for mitochondrial liver function assessment. 244
Growth hormone in inflammatory bowel disease 241
A) Lack of endoscopic visualization of intestinal villi with the "immersion technique" in overt atrophic celiac disease 240
13C-breath tests in the study of microsomal liver function 222
Sacroileitis and peripheral arthropathy associated with ulcerative colitis: effect of infliximab on both articular and intestinal symptoms 215
Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study 209
134C-breath tests in the study of mitochondrial liver function 197
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 196
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 190
Personalized Clinical Phenotyping through Systems Medicine and Artificial Intelligence 189
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study 184
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission. 178
The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease 176
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 175
13C-breath tests in the study of microsomial liver function 175
13C-methionine breath tests for mitochondrial liver function assessment 171
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants. 171
Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. 171
Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. 157
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 155
Association between K469E allele of intercellular adhesion molecule 1 gene and inflammatory bowel disease in different populations. 154
Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab 153
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 151
13C-breath tests in the study of mitochondrial liver function 150
A) Advances in extracorporeal detoxification by MARS dialysis in patients with liver failure 149
Delta13CO2 excretion and expression of dyspeptic symptoms in patients evaluated for Helicobacter pylori infection by [13C] urea breath test 147
ag) Fecal calprotectin in first-degree relatives of patients with ulcerative colitis. 145
A) Study of liver function in healthy elderly subjects using the 13C-methacetin breath test 142
Ileal Crohn's disease: CEUS determination of activity 142
[Helicobacter pylori and gastric carcinoma] 141
Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery? 141
Helicobacter pylori infection affects eosinophilic cationic protein in the gastric juice of patients with idiopathic chronic urticaria 139
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 139
Levofloxacin based regimens for the eradication of Helicobacter pylori 138
Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study 138
Fecal calprotectin in first-degree relatives of patients with ulcerative colitis 137
Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy 135
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 135
Challenges in crohn’s disease management after gastrointestinal cancer diagnosis 134
-Can 13C urea breath test predict resistance to therapy in Helicobacter pylori infection? 133
Efficacy and tolerability of antibiotics in patients undergoing H. pylori eradication 128
Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. 127
The role of inflammatory bowel disease nurses for patients on biologic therapy during the COVID-19 pandemic 127
A) Antibodies to Saccharomyces cerevisiae: are they useful in clinical practice? 126
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 126
A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery 125
Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab 125
Probiotics and Helicobacter pylori eradication 124
Helicobacter pylori CagA-positive strains affect oxygen free radicals generation by gastric mucosa 124
Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. 124
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 121
13C-methacetin breath test for monitoring hepatic function in cirrhotic patients before and after liver transplantation. 120
Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update 119
Helicobacter pylori treatment: a role for probiotics? 118
A novel pathogenic role for microvasculature in inflammatory bowel disease. 118
Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases 117
Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. 114
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis 114
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 113
A) Quantitative evaluation of liver function by the methionine and aminopyrine breath tests in the early stages of liver transplantation 111
Management of perianal fistulas in Crohn's disease: an up-to-date review 111
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 110
Infliximab in Crohn's disease: early and long-term treatment. 110
Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test. 109
Characterization of Sarcopenia in an IBD Population Attending an Italian Gastroenterology Tertiary Center 109
Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases 109
Signs of dissociation and symptoms of post-traumatic stress disorder in inflammatory bowel disease. A case-control study 108
Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. 107
Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders 107
Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease 107
Gender affects 13C-ketoisocaproic acid breath test 106
Biological therapies for inflammatory bowel disease: research drives clinics. 104
Paradoxical arthritis occurring during anti-TNF in patients with Inflammatory Bowel Disease: histological and immunological features of a complex synovitis. 103
Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease 102
Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study. 102
Review article: breath testing for human liver function assessment. 101
Multiparametric Evaluation Predicts Different Mid-Term Outcomes in Crohn's Disease 101
Case report: Dupilumab treatment improved type 2 disorders in a patient with IPEX syndrome diagnosis 100
Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test 99
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? 98
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 98
Saccharomyces cerevisiae-associated diarrhea in an immunocompetent patient with ulcerative colitis 97
A transition clinic model for inflammatory bowel disease between two tertiary care centers: outcomes and predictive factors 97
Epidemiology of inflammatory bowel disease in the Republic of San Marino: The “EPIMICI – San Marino” study 96
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 96
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment 95
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. 95
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 94
Mucosal healing in ulcerative colitis: surveillance or colectomy? 94
Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach 94
Challenges in Crohn's Disease Management after Gastrointestinal Cancer Diagnosis 93
Comment on: Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease 93
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 93
The awareness of the IBD nurse position among patients from an Italian tertiary IBD centre 93
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 92
Promoting psycho-social wellbeing for engaging inflammatory bowel disease patients in their care: an Italian consensus statement 92
Totale 14.974
Salva come PNG Salva come JPEG
Categoria #
all - tutte 92.749
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 92.749
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021644 0 0 0 0 0 44 94 28 149 64 242 23
2021/20221.510 97 120 28 178 43 48 23 246 45 94 269 319
2022/20233.459 421 441 239 540 266 394 163 302 413 98 117 65
2023/20243.061 79 490 61 108 88 270 95 1.196 214 81 179 200
2024/20253.565 67 107 304 82 285 146 181 183 498 378 741 593
2025/20265.216 1.500 305 572 1.065 1.688 86 0 0 0 0 0 0
Totale 22.547